GLPwatch
Papers (10378)
Page 108 of 173, ranked by citation count.
- Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies.
- Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).
- Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model.
- Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.
- Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells.
- A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.
- Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.
- Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
- A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic.
- Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.
- The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
- Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
- Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
- Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.
- Exacerbation of atrial fibrillation related to dulaglutide use.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.
- Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.
- Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
- Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
- GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.
- The need to personalise approaches for the prevention and management of obesity.
- Tirzepatide-Associated Colonic Ischemia.
- Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.
- GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.
- A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol.
- Dietary salt promotes cognition impairment through GLP-1R/mTOR/p70S6K signaling pathway.
- Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release.
- Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo.
- [GLP-1 analogues in treatment of type 1 diabetes mellitus].
- Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
- Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study.
- Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.
- Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model.
- Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
- Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.
- Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
- One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
- [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients].
- Novel ABCA1 peptide agonists with antidiabetic action.
- Unravelling the mechanisms of a protein refolding process based on the association of detergents and co-solvents.
- Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.
- Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.
- Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo.
- A genetic screen identifies Crat as a regulator of pancreatic beta-cell insulin secretion.
- Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving <i>in-situ</i> stability.
- The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
- Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.
- Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration.
- Cardiovascular Outcomes of New Medications for Type 2 Diabetes.
- Polycystic ovary syndrome and type 1 diabetes - the current state of knowledge.
- Dulaglutide as a demethylating agent to improve the outcome of breast cancer.
- Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
- BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
- Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats.
- Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control.
- The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus.
- Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.